This refresh
Data-driven refresh October 8, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,235 tickers); 1,690 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top 30 — quality compounders at a fair price
1. GRND — Grindr Inc. · score 90.3
Software - Application · price $14.94 · 1Y $20.80 · 5Y $30.45 · 10Y $45.18
FCF $154m C · Rev +32.4% A · D/E Negative equity · P/E 31.8x B · PEG 1.12 B+
Why now. Grindr’s premium subscription and ad‑supported model in the global LGBTQ social networking niche is delivering 32.4% revenue growth YoY while maintaining an 18.7% profit margin and generating $154 m of free cash flow. Our Bull Rankings model awards a 90.3/100 quality‑growth score, with Growth as the strongest pillar, underscoring the durability of this compounding top‑line expansion. The market is already pricing in a modest 7% year‑1 FCF growth that tapers to lower rates by year 10—well below the 32.4% revenue surge—so the upside rests on the business continuing to outpace the reverse‑DCF assumptions.
Moat. The Grindr platform is the de‑facto digital gathering place for LGBTQ adults, creating a network effect where users stay because their peers are already there. Premium subscriptions lock in recurring revenue from a highly engaged user base, while ad‑supported services monetize the same audience without cannibalizing the core experience, making switching costly for both users and advertisers.
Risk. The 31.8× trailing P/E signals that the stock is priced for continued high‑growth, yet the Bull Rankings model flags Value as the softest pillar, indicating the price is on the cheap side of peers but still reflects optimism. If revenue growth decelerates toward the reverse‑DCF implied 7% and margins compress, the valuation would collapse, and the stock could retreat toward its 52‑week low of $9.73. A sustained slowdown in subscription uptake would confirm this bear scenario.
Horizon. 1-3 yr $20.80 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $30.45 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $45.18 if current growth sustains into durable earnings power.
2. HRMY — Harmony Biosciences Holdings, Inc. · score 88.6
Biotechnology · price $39.60 · 1Y $47.64 · 5Y $69.74 · 10Y $103.46
FCF $355m C · Rev +24.3% A- · D/E 0.16 B+ · P/E 12.8x A · PEG 0.37 A
Why now. HRMY’s dominant position with WAKIX – the only FDA‑approved pitolisant therapy for narcolepsy – fuels a revenue runway that just posted 24.3% YoY growth, while its 18.9% profit margin and $355 m of free cash flow prove the business can convert that growth into cash. The Bull Rankings model crowns Growth as the strongest pillar (95), so the compounding engine is the expanding rare‑neurology franchise and its pipeline (PWS, DM1). The thesis rests on sustaining that high‑growth, high‑margin trajectory.
Moat. WAKIX’s novel histamine‑H3 antagonism gives HRMY a protected therapeutic niche in narcolepsy, a market with limited alternatives and strong payer reimbursement. The company’s U.S.‑only commercial infrastructure and ongoing Phase 3/2 trials lock in future revenue streams that competitors cannot replicate quickly, cementing a durable edge.
Risk. The price already assumes a slower cash‑flow trajectory (‑16% year‑1 growth fading to 3% by year 10) than the 24.3% revenue surge just delivered, so any stall in pipeline read‑outs or a dip in margin would force the valuation lower. A modest P/E of 12.8 still leaves little room for a earnings slowdown, and a miss in the Phase 3 PWS trial would confirm the bear case.
Horizon. 1-3 yr $47.64 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $69.74 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $103.46 if current growth sustains into durable earnings power.
3. APP — AppLovin Corporation · score 88.4
Advertising Agencies · price $280.12 · 1Y $495.72 · 5Y $725.79 · 10Y $1,077
FCF $4.5b B · Rev +60.6% A · D/E 1.11 C+ · P/E 21.5x B · PEG 0.60 A-
Why now. The bull case hinges on MAX, AppLovin’s AI‑driven in‑app bidding engine, which is rapidly capturing premium mobile inventory and fueling a revenue surge of 60.6% YoY while delivering an industry‑leading 64.6% profit margin. Coupled with a free‑cash‑flow generation of $4.5 B and a market cap of $94.5 B, the business is positioned to compound earnings at a pace that outstrips most peers. The thesis rests on the Bull Rankings model’s strongest pillar—Growth (96)—which signals that this compounding engine will persist as developers double‑down on AI‑optimized monetization.
Moat. MAX creates a sticky network effect: publishers lock in higher yields from real‑time auctions, while developers depend on the platform’s data‑rich optimization to maximize ROI, making switching costly. This AI‑powered loop, reinforced by Adjust’s measurement suite, locks in high‑margin revenue and shields the business from low‑cost rivals.
Risk. The bear case centers on the lofty valuation implied by a P/E of 21.6 and a beta of 2.56, indicating that any slowdown in the 60.6% revenue growth trajectory would sharply compress multiples. A modest dip in growth or a margin squeeze would validate the high‑beta risk and could drive the stock back toward its 52‑week low of $266.84. A sustained deceleration would break the growth‑driven bull thesis.
Horizon. 1-3 yr $495.72 (analyst consensus (n=31)) — fundamentals + valuation re-rating. 5 yr $725.79 at ~21% CAGR — compounding case rests on the competitive position widening. 10 yr $1,077 if current growth sustains into durable earnings power.
4. FICO — Fair Isaac Corporation · score 88
Software - Application · price $707.43 · 1Y $1,113 · 5Y $1,630 · 10Y $2,418
FCF $996m C+ · Rev +24.1% A- · D/E Negative equity · P/E 20.5x B+ · PEG 0.61 A-
Why now. Software - Application · market cap $15.3b. Down 62% from 52-week high of $1858.91 — deep drawdown territory. Revenue growing +24%, comfortably above the S&P median. PEG 0.61 — paying under fair value for the growth rate. 19 sell-side analysts rate this a Buy with a mean 1-yr target of $1,113 (implying +57% upside).
Moat. Net margin 34% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. FCF converts 122% of net income — earnings translate cleanly into cash. Software economics — recurring revenue, embedded customer workflows, and high gross margin all compound the moat once a base account is won. Switching costs are the lever.
Risk. Down 62% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Software — competitive moat is durable until it isn't; watch net revenue retention, gross margin trends, and any new market entrant with a fundamentally lower price point.
Horizon. 1-3 yr $1,113 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $1,630 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $2,418 if current growth sustains into durable earnings power.
5. OSCR — Oscar Health, Inc. · score 87.7
Healthcare Plans · price $33.10 · 1Y $35.40 · 5Y $51.83 · 10Y $76.89
FCF $4.4b B · Rev +27.5% A- · D/E 0.23 B+ · P/E 25.7x B · PEG 1.94 C+
Why now. Oscar’s Oscar platform, which powers broker enrollment and provider engagement, is scaling explosively – revenue is up 27.5% YoY and profit margin already sits at a healthy 3.6%. Coupled with a free‑cash‑flow generation of $4.4B and a market‑cap of only $10.2B, the business is compounding cash on a modest base. The thesis rests on the platform’s ability to lock in new members faster than competitors, keeping the 27.5% growth trajectory alive for years to come.
Moat. The Oscar platform creates a sticky ecosystem for individuals, families and small groups, tying them to Oscar’s brokerage and enrollment tools. This digital front‑end locks in high‑margin members and generates data‑driven pricing power, which underpins the 34.3% ROE – a return only achievable when a health plan can price premium products in a differentiated, tech‑enabled way that rivals can’t replicate quickly.
Risk. The stock trades at a forward P/E of 25.7, well above the sector average, and the Bull Rankings model’s reverse DCF assumes free‑cash‑flow growth will start at a -25% decline, far slower than the 27.5% revenue surge just delivered. If growth stalls or margins compress, the high beta of 2.47 will amplify price drops, and a breach of the 0.23 debt‑to‑equity ceiling would signal leverage stress. A sustained slowdown in platform adoption would trigger the reverse‑DCF’s low‑growth path and push the price back toward the 52‑week low.
Horizon. 1-3 yr $35.40 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $51.83 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $76.89 if current growth sustains into durable earnings power.
6. DLO — DLocal Limited · score 87.3
Software - Infrastructure · price $15.00 · 1Y $18.80 · 5Y $27.53 · 10Y $40.83
FCF $413m C · Rev +46.6% A · D/E 0.12 B+ · P/E 22.1x B+ · PEG 0.64 A-
Why now. DLocal’s cross‑border pay‑in platform for e‑commerce, streaming and ride‑hailing merchants fuels relentless compounding because it unlocks 46.6% revenue growth YoY while delivering $413 m of free cash flow and an elite 34.6% ROE. The network of hundreds of alternative payment methods creates a self‑reinforcing loop that keeps merchants locked in, so the growth engine stays hot. The thesis rests on that high‑velocity payment moat continuing to compound revenue at double‑digit rates.
Moat. The platform’s ability to ingest local cards, bank transfers, cash and dozens of alternative payment methods creates a switching cost that merchants can’t easily replace, especially in emerging markets where DLocal is a category leader. That pricing power translates into a 34.6% ROE, evidence that the business extracts premium returns from its unique payment‑infrastructure stack.
Risk. The Bull Rankings model flags that the current price embeds a reverse‑DCF implied cash‑flow growth of ‑7% in year 1, far below the trailing 46.6% revenue growth, suggesting the market is already pricing in a sharp slowdown. Coupled with a forward P/E of 22.1 and a dilution signal, any further deceleration or missed execution would validate the bear case and crush the upside.
Horizon. 1-3 yr $18.80 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $27.53 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $40.83 if current growth sustains into durable earnings power.
7. NBIX — Neurocrine Biosciences, Inc. · score 87.2
Drug Manufacturers - Specialty & Generic · price $141.25 · 1Y $207.29 · 5Y $303.50 · 10Y $450.22
FCF $870m C+ · Rev +34.4% A · D/E 0.12 B+ · P/E 20.7x B+ · PEG 0.29 A
Why now. NBIX is poised to dominate the high‑margin neuro‑psychiatric niche thanks to INGREZZA, the only FDA‑approved therapy for tardive dyskinesia, which fuels a 34.4% revenue growth and a 20.9% profit margin. The business converts that growth into robust cash generation, delivering $870 m of free cash flow and a low debt‑to‑equity of 0.12, giving shareholders ample runway for reinvestment and buy‑backs. The thesis rests on sustaining the premium pricing power of INGREZZA and expanding Orilissa/Oriahnn into new indications, compounding earnings at a rate that outpaces the modest 6% FCF growth baked into today’s price.
Moat. INGREZZA’s unique mechanism and FDA exclusivity create a high switching cost for neurologists treating tardive dyskinesia, while Orilissa’s proven efficacy in endometriosis locks in a loyal gynecologic specialist base. This product‑centric moat drives a ROE of 19.1%, reflecting pricing power and efficient capital use that competitors cannot replicate without costly clinical trials.
Risk. The market is pricing NBIX for continued double‑digit top‑line expansion, yet the reverse‑DCF assumes FCF growth starting at only 6% and fading, a stark deceleration from the current 34.4% revenue surge. If new indications stall or generic competition erodes INGREZZA’s premium, the 20.7× PE and 0.4 beta could quickly turn the stock into a high‑multiple growth trap. A miss on the next pipeline read‑out would confirm the bear case and crush the upside.
Horizon. 1-3 yr $207.29 (analyst consensus (n=29)) — fundamentals + valuation re-rating. 5 yr $303.50 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $450.22 if current growth sustains into durable earnings power.
8. ADBE — Adobe Inc. · score 86.9
Software - Application · price $241.05 · 1Y $275.06 · 5Y $402.72 · 10Y $597.41
FCF $10.6b A- · Rev +12.0% B+ · D/E 0.58 C+ · P/E 13.5x A- · PEG 0.58 A-
Why now. Adobe’s Digital Media segment powers the creative workflows of photographers, video editors and marketers, and its 12% revenue growth combined with a 28% profit margin fuels a cash‑rich engine. Our Bull Rankings model awards a stellar Quality pillar (92) within an overall 86.9 score, underscoring the business’s durable pricing power and cash generation. Even with a softest pillar of Growth (84), the current PE of 13.5 and PEG of 0.58 signal ample upside, making the next price move hinge on the market recognizing Adobe’s ability to keep compounding its high‑margin cash flow.
Moat. Adobe’s Creative Cloud subscription suite locks in enterprises and creators with deep integration across design, video and experience tools, creating high switching costs and recurring revenue. The 61.9% ROE reflects pricing power derived from category leadership in digital content creation, while the integrated Digital Experience platform expands the addressable market and limits competitor encroachment.
Risk. The Bull Rankings model’s reverse‑DCF shows the stock priced for a near‑term free‑cash‑flow contraction of –2% versus the 12% trailing revenue growth, implying the market is already betting on a slowdown; a sustained deceleration would crush the valuation thesis. Add to that a beta of 1.42 and a debt‑to‑equity of 0.58, which could amplify downside in a market pullback. A miss on growth expectations or a rise in financing costs would confirm the bear case and erode the upside.
Horizon. 1-3 yr $275.06 (analyst consensus (n=32)) — fundamentals + valuation re-rating. 5 yr $402.72 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $597.41 if current growth sustains into durable earnings power.
9. NVDA — NVIDIA Corporation · score 86.2
Semiconductors · price $230.48 · 1Y $328.72 · 5Y $481.27 · 10Y $713.94
FCF $127.0b A · Rev +83.4% A · D/E 0.17 B+ · P/E 29.1x B · PEG 0.29 A
Why now. NVIDIA’s data‑center AI infrastructure dominance fuels an explosive 83.4% revenue growth, backed by a massive $127.0 b free‑cash‑flow and a 63.7% profit margin, making the current price a launchpad for continued compounding in the Compute & Networking segment.
Moat. The Compute & Networking platform locks in hyperscale cloud providers and enterprise AI customers with proprietary GPU architectures that are hard to replicate, while an 84.2% ROE shows pricing power derived from category leadership in AI‑accelerated computing and networking solutions.
Risk. A 2.22 beta and a 29.1 P/E mean the stock is highly sensitive to market swings, and the Bull Rankings model’s reverse‑DCF assumes a 48% FCF growth rate that is already below the 83.4% trailing revenue surge—any slowdown would expose the valuation to a sharp correction.
Horizon. 1-3 yr $328.72 (analyst consensus (n=59)) — fundamentals + valuation re-rating. 5 yr $481.27 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $713.94 if current growth sustains into durable earnings power.
10. INCY — Incyte Corporation · score 84.2
Biotechnology · price $112.75 · 1Y $128.92 · 5Y $188.75 · 10Y $279.99
FCF $1.4b C+ · Rev +21.5% A- · D/E 0.01 A · P/E 14.4x A- · PEG 10.82 D
Why now. Biotechnology · market cap $22.9b. 15% off the 52-week high of $132.60. Revenue growing +21%, comfortably above the S&P median. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $128.92 (implying +14% upside).
Moat. Net margin 27% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 25% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 98% of net income — earnings translate cleanly into cash.
Risk. Reimbursement risk — even an approved drug can fail commercially if payors don't reimburse; pricing pressure from Medicare and large PBMs has been accelerating since 2024.
Horizon. 1-3 yr $128.92 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $188.75 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $279.99 if current growth sustains into durable earnings power.
11. FIVE — Five Below, Inc. · score 83.8
Specialty Retail · price $209.73 · 1Y $310.48 · 5Y $454.57 · 10Y $674.32
FCF $599m C+ · Rev +25.6% A- · D/E 0.82 B · P/E 18.8x B · PEG 0.98 B+
Why now. Five Below’s explosive 25.6% revenue growth is powered by its ever‑expanding teen‑focused candy, party‑goods, and loungewear assortments, and the business is converting that top‑line surge into solid profitability – 11.7% profit margin and a stellar 25% ROE – while generating $599 m of free cash flow. The Bull Rankings model flags Growth as its strongest pillar (94), meaning the compounding of these high‑margin sales will keep the earnings curve steep. The thesis rests on the continuation of this “fun‑first” product mix fueling double‑digit compounding for years to come.
Moat. Five Below locks in its youthful shopper base through a constantly refreshed mix of novelty candy, seasonal party supplies and affordable décor that cannot be replicated overnight; the low‑price, high‑turnover format yields a 25% ROE, reflecting pricing power and efficient inventory turnover that rivals can’t match without sacrificing margins.
Risk. The stock trades at an 18.8× PE, a premium that assumes growth will tumble to the reverse‑DCF implied 9% in year 1 and drift lower over the decade – a stark slowdown from the 25.6% revenue surge just delivered. If top‑line momentum eases toward those modest rates, the valuation collapses; rising leverage (Debt/Equity 0.82) would amplify the downside. A breach of the 9% growth floor would trigger the bear case.
Horizon. 1-3 yr $310.48 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $454.57 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $674.32 if current growth sustains into durable earnings power.
12. CARG — CarGurus, Inc. · score 83.5
Internet Content & Information · price $29.24 · 1Y $41.27 · 5Y $60.43 · 10Y $89.64
FCF $315m C · Rev +13.9% B+ · D/E 0.70 B · P/E 15.6x B+ · PEG 0.62 A-
Why now. The bull case hinges on CarGurus' Digital Deal platform, which turns online shoppers into ready‑to‑buy leads for its dealer network. That engine is powered by 13.9% revenue growth YoY, a 18.2% profit margin and a PE of 15.6x, delivering a compelling earnings runway. With our model’s strongest pillar—Quality at 86—affirming the business’s high ROE of 66.6%, the thesis rests on the platform’s ability to keep compounding this margin‑rich growth.
Moat. CarGurus’ moat lies in its integrated marketplace that locks dealers into subscription fees and advertising while giving shoppers a seamless end‑to‑end experience via Digital Deal. The massive dealer base creates a switching cost: moving to a rival would forfeit the data‑rich lead flow that fuels the 66.6% ROE, a return only achievable through such network‑scale pricing power.
Risk. The bear case focuses on the reverse‑DCF signal that the market assumes free‑cash‑flow growth of –7% in year 1, rising to just 3% by year 10—well below the trailing 13.9% revenue growth, implying pessimism baked into the price. Coupled with a beta of 1.22 and a debt‑to‑equity of 0.7, any slowdown in dealer spend or a shift to competing ad platforms could compress margins and trigger a sell‑off. A sustained miss on the implied FCF growth trajectory would validate the downside.
Horizon. 1-3 yr $41.27 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $60.43 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $89.64 if current growth sustains into durable earnings power.
13. INOD — Innodata Inc. · score 82.8
Information Technology Services · price $61.20 · 1Y $122.75 · 5Y $179.72 · 10Y $266.60
FCF $184m C · Rev +39.0% A · D/E 0.02 A- · P/E 47.4x C+ · PEG 0.87 B+
Why now. INOD is poised to dominate the AI‑training data market as enterprises scramble for high‑quality, labeled datasets; the Digital Data Solutions segment is the engine, delivering 39% YoY revenue growth, 14.7% profit margins and a stellar 29.1%% ROE that fuels cash generation. Those numbers prove the business can reinvest at a rapid clip while returning cash, and the upside hinges on the continued expansion of AI model training demand. The thesis rests on the compounding power of that data moat.
Moat. The DDS segment locks customers into long‑term contracts for AI‑training and post‑training data, creating high switching costs because re‑labeling data is costly and time‑intensive; this pricing power underpins the 29.1% ROE and is reinforced by the Synodex platform’s unique ability to turn medical records into structured data for insurers, a capability few rivals can replicate quickly.
Risk. A P/E of 47.4 and a beta of 2.98 signal that the stock is priced for near‑term optimism, while the Bull Rankings model’s reverse‑DCF assumes only a 10% FCF growth start‑point—well below the 39% revenue surge just delivered—so any slowdown in AI data demand would expose the valuation and could crush the upside. Confirmation of the bear case would be a miss on revenue growth or a widening of the P/E to >60.
Horizon. 1-3 yr $122.75 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $179.72 at ~24% CAGR — compounding case rests on the competitive position widening. 10 yr $266.60 if current growth sustains into durable earnings power.
14. NFLX — Netflix, Inc. · score 82.3
Entertainment · price $71.57 · 1Y $92.55 · 5Y $135.50 · 10Y $201.01
FCF $11.2b A- · Rev +16.0% B+ · D/E 0.55 B+ · P/E 22.5x B · PEG 1.17 B+
Why now. Netflix’s unrivaled global streaming library fuels a compounding revenue growth of 16% while delivering a profit margin of 28.2% and an extraordinary ROE of 45.3%, proving the business can reinvest earnings at a premium rate. Our Bull Rankings model rates the company at an 82.3 quality‑growth score, with Quality as the strongest pillar, underscoring the durability of its content moat and pricing power. The thesis hinges on continued subscriber expansion in emerging markets that keeps the 16% growth trajectory alive.
Moat. Netflix’s massive catalog of TV series, documentaries, feature films, games and live programming across languages creates a high switching cost for members who have built personal watchlists and habit loops on the platform. The 45.3% ROE reflects pricing power derived from category leadership in on‑demand streaming, allowing the company to capture more value than peers without a comparable content breadth.
Risk. The premium P/E of 22.5 signals that the market has already priced in lofty growth expectations, and the reverse‑DCF shows the current price assumes a first‑year free‑cash‑flow growth of about 30%—far above the trailing 16% revenue growth, leaving little margin for error if subscriber churn spikes or content costs surge. A sustained slowdown to sub‑10% revenue growth would validate the high beta of 1.61 and could force the stock back toward its 52‑week low of $65.08, breaking the bull case.
Horizon. 1-3 yr $92.55 (analyst consensus (n=45)) — fundamentals + valuation re-rating. 5 yr $135.50 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $201.01 if current growth sustains into durable earnings power.
15. PGY — Pagaya Technologies Ltd. · score 81.9
Software - Infrastructure · price $18.26 · 1Y $28.82 · 5Y $42.19 · 10Y $62.59
FCF $252m C · Rev +25.6% A- · D/E 1.34 C · P/E 13.2x A- · PEG 0.03 A
Why now. The bull case hinges on Pagaya’s Decline Monetization engine, which monetizes rejected loan applications and fuels a revenue surge of 25.6% YoY while delivering a solid 9.1% profit margin and an attractive P/E of 13.2, positioning the stock as a cheap growth story. The AI‑driven platform locks in institutional partners, creating a compounding revenue tail that should keep growth alive. The thesis rests on the ability to expand the network and capture more declined loans, driving continued margin expansion.
Moat. Pagaya’s moat lives in its proprietary AI‑powered Decline Monetization and Dual Look platforms, which embed deep data models into partner loan workflows, making switching costly for banks and fintechs. This stickiness translates into a high ROE of 19.5%, reflecting pricing power from being the go‑to partner for extracting value from otherwise lost credit opportunities.
Risk. The bear case centers on the stock’s extreme volatility (beta 5.52) and a balance sheet that carries a debt‑to‑equity of 1.34, which could amplify downside in a credit‑cycle slowdown. Moreover, the Bull Rankings model’s reverse DCF assumes free‑cash‑flow growth starting at –7% a year in year 1, fading steadily, a stark contrast to the reported 25.6% revenue growth, indicating that the market may already be pricing in a sharp deceleration. A sustained slowdown in loan‑originations or a loss of partner contracts would validate this risk.
Horizon. 1-3 yr $28.82 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $42.19 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $62.59 if current growth sustains into durable earnings power.
16. PODD — Insulet Corporation · score 81.7
Medical Devices · price $134.47 · 1Y $170.96 · 5Y $250.30 · 10Y $371.30
FCF $294m C · Rev +29.4% A- · D/E 0.67 C+ · P/E 25.2x B · PEG 1.06 B+
Why now. The Omnipod 5 automated insulin delivery system is unlocking a new wave of recurring revenue as patients migrate from pump‑only solutions to a fully integrated AID platform. Insulet is delivering 29.4% YoY revenue growth, backed by a 12.3% profit margin and $294 m of free‑cash‑flow, which together fuel a compounding engine that can sustain double‑digit earnings expansion. The thesis hinges on the continued roll‑out of the Omnipod 5 algorithm and its Bluetooth‑linked CGM partnership, which locks in patients for the long haul.
Moat. Insulet’s moat stems from the Omnipod platform’s proprietary AID algorithm embedded in a disposable pod that communicates wirelessly with third‑party CGMs, creating a high switching cost for users accustomed to the seamless, pump‑free experience. This technical lock‑in, combined with a ROE of 26.4% driven by pricing power as the market’s only tubeless, Bluetooth‑enabled system, protects margins and deters copycats.
Risk. The stock trades at a forward P/E of 25.2, well above many medical‑device peers, and the Bull Rankings model’s reverse‑DCF shows the implied free‑cash‑flow growth fading from 25% to 3% over ten years, signaling that the market may be pricing in overly optimistic growth. A slowdown in revenue growth below 20% or a margin dip would validate the bear case and could trigger a sharp correction.
Horizon. 1-3 yr $170.96 (analyst consensus (n=23)) — fundamentals + valuation re-rating. 5 yr $250.30 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $371.30 if current growth sustains into durable earnings power.
17. GMED — Globus Medical, Inc. · score 81.6
Medical Devices · price $73.33 · 1Y $100.92 · 5Y $147.76 · 10Y $219.19
FCF $756m C+ · Rev +19.7% B+ · D/E 0.02 A- · P/E 18.8x A- · PEG 1.49 B
Why now. The spine‑fusion franchise—pedicle‑screw and rod systems—anchors GMED’s growth as hospitals double‑down on minimally invasive solutions. The business is delivering 19.7% revenue growth, 17% profit margin and $756 m of free‑cash‑flow, fueling a compounding earnings runway that the market hasn’t fully priced in. The thesis hinges on that growth persisting as the U.S. musculoskeletal‑disorder market expands.
Moat. GMED’s end‑to‑end spine platform, spanning traditional fusion, motion‑preservation and vertebral‑compression products, locks surgeons and hospitals into a single supplier ecosystem, creating high switching costs. Coupled with a razor‑thin debt‑to‑equity of 0.02 and an ROE of 11.2%, the company turns its capital efficiency into a defensible pricing advantage that rivals can’t replicate quickly.
Risk. The Bull Rankings model’s reverse‑DCF assumes near‑zero FCF growth in year 1, a stark contrast to the reported 19.7% revenue growth, suggesting the current price embeds optimism that may be premature; a slowdown to sub‑20% growth would crush the upside. The modest P/E of 18.8 and beta of 0.96 still leave the stock vulnerable to a broader market pullback, and any margin compression would validate the bear case.
Horizon. 1-3 yr $100.92 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $147.76 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $219.19 if current growth sustains into durable earnings power.
18. GOOG — Alphabet Inc. · score 81.6
Internet Content & Information · price $344.86 · 1Y $419.65 · 5Y $614.40 · 10Y $911.43
FCF $53.3b A · Rev +20.1% A- · D/E 0.19 A- · P/E 17.3x B · PEG 1.23 B
Why now. Internet Content & Information · market cap $4.2T. 15% off the 52-week high of $404.47. Revenue growing +20%, comfortably above the S&P median. 14 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $419.65 (implying +22% upside).
Moat. Net margin 55% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 38% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $4.2T market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $419.65 (analyst consensus (n=14)) — fundamentals + valuation re-rating. 5 yr $614.40 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $911.43 if current growth sustains into durable earnings power.
19. CPAY — Corpay, Inc. · score 81.4
Software - Infrastructure · price $402.08 · 1Y $461.00 · 5Y $674.95 · 10Y $1,001
FCF $1.6b C+ · Rev +20.4% A- · D/E 2.75 D · P/E 24.4x B+ · PEG 0.78 A-
Why now. Corpay’s corporate payments platform—especially its cross‑border and AP‑modernization solutions—is scaling at a blistering 20.4% revenue growth while delivering a 22.7% profit margin and a stellar 32.2% ROE. Our Bull Rankings model gives CPAY an 81.4/100 quality‑growth score, with Growth as the strongest pillar, underscoring that the business’s compounding engine is still roaring. Because the reverse‑DCF assumes only ~4% cash‑flow growth—well below the trailing 20% top‑line pace—the market is pricing in pessimism, making the current price a launchpad for upside.
Moat. The moat lives in Corpay’s integrated spend‑management suite—virtual cards, T&E cards, and AP modernization—that locks large enterprises into a single, data‑rich payment ecosystem, creating high switching costs. That stickiness fuels the 32.2% ROE, reflecting pricing power from being the de‑facto provider for corporate expense workflows across the Vehicle, Lodging, and Corporate Payments segments.
Risk. The bears point to a heavy debt load (Debt‑to‑Equity 2.75) and a forward‑looking P/E of 24.4, which is lofty for a name that must sustain 20% growth to justify the multiple. If revenue growth decelerates toward the reverse‑DCF’s 4% cash‑flow assumption, margin pressure could erode the 22.7% profit margin and trigger a sell‑off. A sustained slowdown in corporate travel or fleet spending would be the trigger that validates this risk.
Horizon. 1-3 yr $461.00 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $674.95 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $1,001 if current growth sustains into durable earnings power.
20. GOOGL — Alphabet Inc. · score 81.1
Internet Content & Information · price $348.29 · 1Y $429.47 · 5Y $628.79 · 10Y $932.77
FCF $53.3b A · Rev +20.1% A- · D/E 0.19 A- · P/E 17.5x B · PEG 1.24 B
Why now. Alphabet’s AI‑powered Search and YouTube ad engine is still expanding at a blistering 20.1% revenue growth while converting that into a rock‑solid 54.8% profit margin and a staggering 38.1% ROE. Those fundamentals sit under a Quality‑Growth score of 81.1, with Growth as the strongest pillar, confirming that the compounding engine is real and durable. The whole thesis hinges on the ability of Search and YouTube to keep scaling ad spend faster than any competitor can catch up.
Moat. The Search and YouTube platforms lock in users through network effects – every query and video view feeds data that sharpens ad targeting, creating a self‑reinforcing loop competitors can’t duplicate quickly. This data moat fuels pricing power, which is evident in Alphabet’s >38% ROE, far above the sector average, and underwrites its ability to command premium ad rates across global markets.
Risk. The Bull Rankings model assumes a reverse‑DCF implied FCF growth of ~54% in year 1, far above the trailing 20.1% revenue growth, meaning the current price already embeds aggressive optimism; a slowdown to the historical growth path would crush the valuation. Add to that a beta of 1.21 and a forward P/E of 17.5, which, while not sky‑high, signals that any earnings miss could trigger a sharp correction. The bear case materialises if ad spend stalls and the implied growth premium evaporates.
Horizon. 1-3 yr $429.47 (analyst consensus (n=54)) — fundamentals + valuation re-rating. 5 yr $628.79 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $932.77 if current growth sustains into durable earnings power.
21. DXCM — DexCom, Inc. · score 80.9
Medical Devices · price $84.41 · 1Y $96.23 · 5Y $140.89 · 10Y $209.00
FCF $1.4b C+ · Rev +15.5% B+ · D/E 0.53 B · P/E 33.5x C+ · PEG 1.28 B
Why now. Medical Devices · market cap $31.9b. 9% off the 52-week high of $92.59. Revenue growing +16%, comfortably above the S&P median. 26 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $96.23 (implying +14% upside).
Moat. Net margin 20% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 38% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 141% of net income — earnings translate cleanly into cash.
Risk. Beta 1.48 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 33x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $96.23 (analyst consensus (n=26)) — fundamentals + valuation re-rating. 5 yr $140.89 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $209.00 if current growth sustains into durable earnings power.
22. COCO — The Vita Coco Company, Inc. · score 80.6
Beverages - Non-Alcoholic · price $55.98 · 1Y $79.90 · 5Y $116.98 · 10Y $173.53
FCF $124m C · Rev +26.1% A- · D/E 0.04 A · P/E 30.9x C · PEG 1.83 C+
Why now. Beverages - Non-Alcoholic · market cap $2.9b. Down 41% from 52-week high of $85.83 — deep drawdown territory. Revenue growing +26% — in hypergrowth territory. 10 sell-side analysts rate this a Buy with a mean 1-yr target of $79.90 (implying +58% upside).
Moat. Net margin 16% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 27% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 114% of net income — earnings translate cleanly into cash.
Risk. Down 41% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $79.90 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $116.98 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $173.53 if current growth sustains into durable earnings power.
23. EXLS — ExlService Holdings, Inc. · score 80.4
Information Technology Services · price $36.87 · 1Y $44.63 · 5Y $65.34 · 10Y $96.92
FCF $297m C · Rev +13.4% B+ · D/E 0.57 C+ · P/E 23.3x B+ · PEG 0.92 B+
Why now. EXLS’s AI‑driven claims management platform for insurers is scaling at a 13.4% revenue growth while delivering a 32.3% ROE, proving that its high‑margin analytics can be priced into contracts. The Bull Rankings model gives the stock an 80.4/100 quality‑growth score, with Quality as the strongest pillar, underscoring the durability of its cash‑generating engine. Combined with a $297 m free‑cash‑flow run‑rate, the thesis rests on the ability to compound this cash into buybacks and reinvest in the same high‑margin segments.
Moat. The company’s deep integration into insurance workflows—claims processing, underwriting support, and policy servicing—creates switching costs for carriers that must re‑engineer complex data pipelines to leave EXLS. Its 32.3% ROE reflects pricing power derived from being the preferred analytics partner across the Insurance segment, a moat that competitors can’t replicate quickly without massive data and AI investments.
Risk. A bear sees the valuation premium baked in: the stock trades at a forward P/E of 23.3 despite a 13.4% growth rate, and the Bull Rankings model’s Value pillar (72) signals the price is already on the cheap side of peers, leaving little upside if growth slows. A dip in insurance spend or a shift to lower‑cost AI vendors could compress margins, and a rise in debt‑to‑equity above 0.57 would confirm the downside. The key risk trigger is a sustained slowdown in revenue growth below 10% YoY, which would validate the current modest valuation and cap the upside.
Horizon. 1-3 yr $44.63 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $65.34 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $96.92 if current growth sustains into durable earnings power.
24. DECK — Deckers Outdoor Corporation · score 79.2
Footwear & Accessories · price $82.56 · 1Y $120.41 · 5Y $176.29 · 10Y $261.52
FCF $1.1b C+ · Rev +7.9% B · D/E 0.21 A- · P/E 11.7x A- · PEG 1.00 B+
Why now. The Bull Rankings model gives Deckers a Quality‑growth score of 79.2, with Quality at a blistering 96 – the strongest pillar – meaning the business is cash‑rich, high‑margin and returns capital at a 44.1% ROE. That strength is anchored in its premium UGG and HOKA footwear lines, which are driving a 7.9% revenue growth and an 18.4% profit margin. With the stock trading at a $82.56 price that assumes a -4% FCF growth start versus the 7.9% top‑line growth we just delivered, the market is pricing in a slowdown that isn’t evident – the upside rests on the continuation of this premium‑segment compounding.
Moat. Deckers’ moat lives in its category‑leadership of high‑priced lifestyle and performance shoes – UGG dominates the premium sheepskin market, HOKA leads the performance‑running segment, and Teva owns the outdoor‑sandals niche. This portfolio commands pricing power that fuels the 44.1% ROE, and the entrenched retail and e‑commerce distribution network makes switching costly for consumers who seek the specific fit and heritage of each brand.
Risk. The softest pillar is Growth at 67, signaling that revenue momentum could falter; the reverse‑DCF shows a -4% FCF growth start, a stark contrast to the current 7.9% YoY increase. If the premium footwear market cools or a competitor erodes HOKA’s share, growth could slip below the model’s expectations, and the stock would regress toward its 52‑week low of $77.20. A sustained deceleration would validate the bearish view.
Horizon. 1-3 yr $120.41 (analyst consensus (n=22)) — fundamentals + valuation re-rating. 5 yr $176.29 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $261.52 if current growth sustains into durable earnings power.
25. MELI — MercadoLibre, Inc. · score 78.8
Internet Retail · price $1856.66 · 1Y $2,276 · 5Y $3,332 · 10Y $4,943
FCF $12.4b A- · Rev +46.0% A · D/E 1.69 C+ · P/E 50.5x D · PEG 1.01 B+
Why now. The bull case hinges on MercadoLibre’s dominant Mercado Pago ecosystem, which is fueling a 46% revenue growth and generating $12.4B of free cash flow, underpinning a PE of 50.5 that still reflects massive upside. Our Bull Rankings model awards a Growth pillar of 96, confirming that the compounding power of its fintech suite will keep the business expanding at double‑digit rates, while the current price already embeds a modest 8% FCF growth assumption—well below the 46% top‑line pace—making the valuation pessimistic. The thesis rests on the persistence of this fintech‑driven growth, which should keep the stock on a steep upside trajectory.
Moat. MELI’s moat lives in the integrated Mercado Pago platform, which locks merchants and consumers into a seamless payments‑and‑credit loop, creating high switching costs and network effects that competitors can’t replicate quickly. The resulting pricing power is evident in a ROE of 23.8%, driven by the ability to cross‑sell credit and investment products (Mercado Credito, Mercado Fondo) to a captive user base across Brazil, Mexico, and Argentina.
Risk. The bear case centers on the elevated valuation: a PE of 50.5 and a beta of 1.31 signal that any slowdown in the 46% revenue surge or a margin squeeze could trigger a sharp correction, especially as the reverse‑DCF assumes a negative 8% FCF growth in year 1. A dip in growth or a rise in debt‑to‑equity above 1.69 would validate the pessimistic view, and a breach of the 52‑week low at $1,495 would confirm the risk.
Horizon. 1-3 yr $2,276 (analyst consensus (n=26)) — fundamentals + valuation re-rating. 5 yr $3,332 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $4,943 if current growth sustains into durable earnings power.
26. SE — Sea Limited · score 78
Internet Retail · price $92.89 · 1Y $154.93 · 5Y $226.84 · 10Y $336.49
FCF $4.5b B · Rev +36.4% A · D/E 0.32 A- · P/E 35.9x C · PEG 0.93 B+
Why now. Sea’s explosive 36.4% revenue growth in FY 2025 is powered by Shopee’s mobile‑first marketplace expanding across Southeast Asia and Latin America, while Garena fuels engagement with high‑margin digital games. The business converts that top‑line surge into $4.5 B free cash flow and a healthy 6.9% profit margin, giving the stock a PEG of 0.93 that signals growth at a reasonable price. The thesis rests on the continuation of this compounding growth engine, which our model flags as its strongest pillar – Growth.
Moat. Shopee’s end‑to‑end ecosystem – from integrated payments to proprietary logistics – locks merchants and consumers into a network that rivals can’t replicate quickly, while Garena’s game platform creates sticky user bases and in‑game monetisation that deepen engagement and generate recurring revenue.
Risk. The Bull Rankings model flags “diluting shareholders,” and with a beta of 1.55 the stock is highly volatile; the current P/E of 35.9 is elevated for a growth name, and the reverse‑DCF implies only 9% FCF growth in year 1 versus the 36.4% revenue surge just delivered, suggesting the market may be pricing in a slowdown. A material equity raise or a sustained miss on growth would confirm the bear case and erode the upside.
Horizon. 1-3 yr $154.93 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $226.84 at ~20% CAGR — compounding case rests on the competitive position widening. 10 yr $336.49 if current growth sustains into durable earnings power.
27. CART — Maplebear Inc. · score 77.7
Internet Retail · price $46.30 · 1Y $58.21 · 5Y $85.23 · 10Y $126.44
FCF $1.2b C+ · Rev +12.6% B+ · D/E 0.01 A · P/E 25.3x C+ · PEG 1.84 C+
Why now. Instacart’s Marketplace is rapidly becoming the default fulfillment layer for grocery retailers, and that stickiness fuels a 12.6% revenue growth while delivering $1.2 B of free cash flow and a 20.7% ROE. Those fundamentals underpin a compounding engine that can keep earnings expanding well beyond the next year, making the stock a clear buy at today’s price. The thesis rests on the Marketplace’s ability to lock in more retailer contracts and drive ad spend, which will keep the growth curve alive.
Moat. The Instacart Enterprise platform embeds end‑to‑end technology into retailer operations, creating high switching costs for grocery chains that have integrated inventory, order routing, and advertising data. This deep integration, combined with the ability to monetize shopper insights via Instacart Ads, translates into pricing power that fuels the current 20.7% ROE and cannot be replicated quickly by generic e‑commerce players.
Risk. The Bull Rankings model flags that the current price assumes a declining free‑cash‑flow growth of –10% in year 1, well below the trailing 12.6% revenue growth, indicating the market is already pricing in a slowdown. Coupled with a forward P/E of 25.3 and a beta of 0.87, any further deceleration in growth or margin compression would validate the bearish view and could push the stock back toward its 52‑week low.
Horizon. 1-3 yr $58.21 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $85.23 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $126.44 if current growth sustains into durable earnings power.
28. LLY — Eli Lilly and Company · score 77.4
Drug Manufacturers - General · price $1169.60 · 1Y $1,329 · 5Y $1,946 · 10Y $2,887
FCF $13.6b A- · Rev +49.6% A · D/E 1.62 C · P/E 39.3x C+ · PEG 1.12 B+
Why now. Drug Manufacturers - General · market cap $1.0T. 10% off the 52-week high of $1292.65. Revenue growing +50% — in hypergrowth territory. 29 sell-side analysts rate this a Buy with a mean 1-yr target of $1,329 (implying +14% upside).
Moat. Net margin 34% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 79% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $1.0T market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk. Trailing P/E 39x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. P/S 13.1x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon. 1-3 yr $1,329 (analyst consensus (n=29)) — fundamentals + valuation re-rating. 5 yr $1,946 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $2,887 if current growth sustains into durable earnings power.
29. YUMC — Yum China Holdings, Inc. · score 77
Restaurants · price $41.78 · 1Y $61.91 · 5Y $90.65 · 10Y $134.47
FCF $940m C+ · Rev +8.8% B · D/E 0.38 A- · P/E 15.3x B+ · PEG 0.91 B+
Why now. Yum China’s dominance in the KFC and Pizza Hut franchise network fuels a relentless cash engine – $940 m of free‑cash‑flow, 7.8% profit margin and 8.8% revenue growth YoY – all while trading at a modest 15.3× P/E. Our Bull Rankings model gives YUMC a 77‑point quality‑growth score, with Quality as the strongest pillar, underscoring the durability of its brand‑led operating model. The reverse‑DCF shows the market is pricing only a 4% FCF growth start, below the 8.8% revenue pace, meaning the upside is still largely un‑priced.
Moat. The KFC and Pizza Hut footprints give YUMC a massive, city‑level real‑estate moat; each outlet sits in high‑traffic malls and streets, locking in footfall that rivals can’t replicate quickly. Coupled with a proprietary online delivery platform, the chain extracts pricing power that lifts ROE to 18.2%, a clear sign that the franchise network translates into superior returns.
Risk. The softest pillar in our model is Growth, and the 8.8% revenue rise is already modest for a fast‑food leader; any slowdown would clash with the 4% implied FCF growth baked into today’s price. A P/E of 15.3, while reasonable, still reflects optimism that margins stay flat; a margin dip or a slowdown in same‑store sales would push the stock toward its 52‑week low of $39.72 and invalidate the bull thesis.
Horizon. 1-3 yr $61.91 (analyst consensus (n=20)) — fundamentals + valuation re-rating. 5 yr $90.65 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $134.47 if current growth sustains into durable earnings power.
30. MLI — Mueller Industries, Inc. · score 76.9
Metal Fabrication · price $60.49 · 1Y $69.56 · 5Y $101.85 · 10Y $151.08
FCF $666m C+ · Rev +14.8% B+ · D/E 0.01 A · P/E 15.8x A- · PEG 3.41 D
Why now. Metal Fabrication · market cap $13.4b. 15% off the 52-week high of $71.12. Revenue growing +15%, comfortably above the S&P median.
Moat. Net margin 18% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 24% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $69.56 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $101.85 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $151.08 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.